Abstract | PURPOSE: METHODS: RESULTS: Mean best-corrected visual acuity (BCVA) at presentation remained within the range 0.23-0.24 Snellen and the median patient age within 79-80 years, whereas BCVA at first visit after the third injection increased from 0.24 to 0.31 (p < 0.0001) in concert with a shift in preferred practice from separate-day injection to same-day injection. This led to a reduction in the median time to treatment from 16 days to 1 day. The proportion of patients with fellow-eye BCVA 0.05 or worse at presentation with newly diagnosed wet AMD in the incident eye decreased from 38% to 22% (p < 0.0018). The proportion of bilaterally treated patients increased during the study period. CONCLUSION: In this study, 2-week-earlier injection was associated with the equivalent of a 5-Early Treatment Diabetic Retinopathy Study letter-gain in mean visual acuity at 3 months after presentation. The difference is larger than expected from the 2-week-longer duration of disease at the study end-point. The study supports that early diagnosis and treatment of nAMD is of value for functional outcomes.
|
Authors | Annette Rasmussen, Sara Brandi, Josefine Fuchs, Louise H Hansen, Henrik Lund-Andersen, Birgit Sander, Michael Larsen |
Journal | Acta ophthalmologica
(Acta Ophthalmol)
Vol. 93
Issue 7
Pg. 616-20
(Nov 2015)
ISSN: 1755-3768 [Electronic] England |
PMID | 26073051
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2015 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd. |
Chemical References |
- Angiogenesis Inhibitors
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- Ranibizumab
|
Topics |
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors
(therapeutic use)
- Female
- Humans
- Intravitreal Injections
- Male
- Ranibizumab
(therapeutic use)
- Retrospective Studies
- Time-to-Treatment
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
- Visual Acuity
(physiology)
- Wet Macular Degeneration
(diagnosis, drug therapy, physiopathology)
|